EGFR and renal cell carcinoma: Another study revealed SMYD3 as a mediator between the von Hippel‒Lindau/hypoxia-inducible factor α (VHL-HIFα) axis and epidermal growth factor receptor (EGFR) in renal cell carcinoma.